logo
Site Network

Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Fondazione IRCCS Istituto Nazionale dei Tumori

+390223901
direzione.scientifica@istitutotumori.mi.it
Source: Site record.
http://www.istitutotumori.mi.it

Claim This Site

Are you the site administrator? Claim this site to update information.

Basic Information

Site Overview

Source: Human-provided.

Fondazione IRCCS Istituto Nazionale dei Tumori (INT) is a world-renowned public hospital and premier oncology reference center. Established in 1928, it operates as a government-designated Scientific Institute for Research and Treatment (IRCCS) and is recognized as a Comprehensive Cancer Centre by the Organisation of European Cancer Institutes (OECI).

Business Status

Source: Human-provided. OPEN

Business Category

Source: Human-provided. Research institute

Business Subcategory

Source: Human-provided. Research institute
Source: Trial-derived.
280Total Trials
Source: Trial-derived.
70Recruiting Trials
Source: Trial-derived.
82Active Trials
Source: Trial-derived.
0Completed Trials
Source: Trial-derived.
359Unique Conditions
Source: Trial-derived.
199Unique Sponsors

Conditions

Source: Trial-derived. Breast Cancer (13)Source: Trial-derived. Carcinoma, Non-Small-Cell Lung (12)Source: Trial-derived. Melanoma (12)Source: Trial-derived. Solid Tumors (10)Source: Trial-derived. Ovarian Cancer (9)Source: Trial-derived. Colorectal Cancer (6)Source: Trial-derived. Renal Cell Carcinoma (6)Source: Trial-derived. Advanced Solid Tumor (5)

Sponsors

Source: Trial-derived. Merck Sharp & Dohme LLC (37)Source: Trial-derived. Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (29)Source: Trial-derived. Hoffmann-La Roche (21)Source: Trial-derived. Daiichi Sankyo (15)Source: Trial-derived. Janssen Research & Development, LLC (14)Source: Trial-derived. Incyte Corporation (11)Source: Trial-derived. Amgen (9)Source: Trial-derived. Bristol-Myers Squibb (9)

Research Technology

Research technology inferred from trial participation

Source: AI-inferred. Electronic data capture

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. Electrocardiography (lead count not stated)
Source: AI-inferred. MRI
Source: AI-inferred. CT Scan
Source: AI-inferred. SPECT / nuclear medicine

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. Timed pharmacokinetic sampling and processing
Source: AI-inferred. Specimen packaging and shipment
Source: AI-inferred. Histology / pathology
Source: AI-inferred. Immunogenicity (anti-drug antibody) testing
Source: AI-inferred. Pharmacokinetic bioanalysis
Source: AI-inferred. PCR / molecular
Source: AI-inferred. Sequencing / genomics

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling
Source: AI-inferred. Sterile preparation (laminar-flow hood / BSC or cleanroom)

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration
Source: AI-inferred. Surgery / operating room

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot

Additional Capabilities

Other capabilities inferred from trial participation

Source: AI-inferred. Bladder mapping biopsies
Source: AI-inferred. Cystoscopy
Source: AI-inferred. EGFR mutation and ALK rearrangement testing
Source: AI-inferred. EGFR mutation testing
Source: AI-inferred. Intravesical drug instillation
Source: AI-inferred. Left ventricular ejection fraction assessment
Source: AI-inferred. Left ventricular ejection fraction measurement
Source: AI-inferred. RAS mutation testing